Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPG302 in Healthy Volunteers and ALS Participants
NCT05882695Phase 1Completed
- Sponsor
- Spinogenix
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tazbentetol in amyotrophic lateral sclerosis (ALS) (7 arms), sponsored by Spinogenix. Primary endpoints: Safety and tolerability in healthy volunteers (SAD cohort) at 7 days, Safety and tolerability in healthy volunteers (SAD food effect cohort) at 15 days and 2 more. Started Jul 2023; status: completed.
02
Drugs
tazbentetol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05882695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05882695.